

CADTH Reference List

Antiviral Treatment for COVID-19 in Adults With Renal Impairment

November 2022

Authors: Candice Madakadze, Quenby Mahood

Cite As: *Antiviral Treatment for COVID-19 in Adults With Renal Impairment*. (CADTH reference list). Ottawa: CADTH; 2022 Nov.

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up to date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein do not necessarily reflect the views of Health Canada, Canada's provincial or territorial governments, other CADTH funders, or any third-party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

Funding: CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

Questions or requests for information about this report can be directed to requests@cadth.ca

Key Messages

- We did not find any studies about the clinical effectiveness of nirmatrelvir and ritonavir for COVID-19 in adults with renal impairment.
- We found 1 systematic review and 7 non-randomized studies about the clinical effectiveness of remdesivir for COVID-19 in adults with renal impairment.
- We did not find any evidence-based guidelines for the use of nirmatrelvir and ritonavir for COVID-19 in adults with renal impairment.
- We found 1 evidence-based guideline for the use of remdesivir for COVID-19 in adults with renal impairment.

Research Questions

1. What is the clinical effectiveness of nirmatrelvir and ritonavir for COVID-19 in adults with renal impairment?
2. What is the clinical effectiveness of remdesivir for COVID-19 in adults with renal impairment?
3. What are the evidence-based guidelines for the use of nirmatrelvir and ritonavir for COVID-19 in adults with renal impairment?
4. What are the evidence-based guidelines for the use of remdesivir for COVID-19 in adults with renal impairment?

Methods

Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Database of Systematic Reviews, the International HTA Database, the websites of Canadian and major international health technology agencies, as well as a focused internet search. The search strategy comprised both controlled vocabulary, such as the National Library of Medicine's MeSH (Medical Subject Headings), and keywords. The main search concepts were COVID-19 and renal impairment and remdesivir or nirmatrelvir and ritonavir (Paxlovid). A CADTH-developed search filter was applied to limit retrieval to guidelines for a secondary search of concepts COVID-19 and remdesivir or nirmatrelvir and ritonavir (Paxlovid). Conference abstracts were omitted from the Embase search. The search was completed on November 16, 2022, and limited to English-language documents published since January 1, 2020. Internet links were provided, where available.

Selection Criteria

One reviewer screened literature search results (titles and abstracts) and selected publications according to the inclusion criteria presented in [Table 1](#). Full texts of study publications were not reviewed. Open access full-text versions of evidence-based guidelines were reviewed when available.

Table 1: Selection Criteria

Criteria	Description
Population	Adults with renal impairment and symptomatic COVID-19
Intervention	Q1 and Q3: Nirmatrelvir and ritonavir Q2 and Q4: Remdesivir
Comparator	Q1 and Q2: Any comparator (e.g., standard care, placebo, no treatment); no comparator Q3 and Q4: Not applicable
Outcomes	Q1 and Q2: Clinical benefits (e.g., mortality, hospitalization, severity of clinical symptoms, viral load, time to clinical improvement) and harms (e.g., adverse events, intolerability) Q3: Recommendations regarding the use of nirmatrelvir and ritonavir for COVID-19 Q4: Recommendations regarding the use of remdesivir for COVID-19
Study designs	Health technology assessments, systematic reviews, randomized controlled trials, non-randomized studies, evidence-based guidelines

Results

One systematic review¹ and 7 non-randomized studies²⁻⁸ were identified regarding the clinical effectiveness of remdesivir for COVID-19 in adults with renal impairment. One evidence-based guideline⁹ was identified regarding the use of remdesivir for COVID-19 in adults with renal impairment. No relevant health technology assessments or randomized controlled trials were identified.

Additional references of potential interest that did not meet the inclusion criteria are provided in [Appendix 1](#).

References

Health Technology Assessments

No literature identified.

Systematic Reviews

1. Davoudi-Monfared E, Ahmadi A, Karimpour-Razkenari E, Shahrami B, Najmeddin F, Mojtahedzadeh M. Remdesivir administration in COVID-19 patients with renal impairment: a systematic review. *Am J Ther.* 2022;29(5):e520-e533. [PubMed](#)

Randomized Controlled Trials

No literature identified.

Non-Randomized Studies

2. Seethapathy R, Zhao S, Long JD, Strohhahn IA, Sise ME. A propensity score-matched observational study of remdesivir in patients with COVID-19 and severe kidney disease. *Kidney360.* 2022;3(2):269-278. [PubMed](#)
3. Selvaraj V, Lal A, Finn A, et al. Efficacy of remdesivir for hospitalized COVID-19 patients with end stage renal disease. *World J Crit Care Med.* 2022;11(1):48-57. [PubMed](#)
4. Shah MK, Parikh M, Prajapati D, et al. Safety and tolerability of remdesivir in patients with end-stage renal disease on maintenance hemodialysis. *Indian J Crit Care Med.* 2022;26(5):619-625. [PubMed](#)
5. Stancampiano F, Jhawar N, Alsafi W, et al. Use of remdesivir for COVID-19 pneumonia in patients with advanced kidney disease: a retrospective multicenter study. *Clin Infect Pract.* 2022;16:100207. [PubMed](#)
6. Wang S, Huynh C, Islam S, Malone B, Masani N, Joseph D. Assessment of safety of remdesivir in Covid - 19 patients with estimated glomerular filtration rate (eGFR) < 30 ml/min per 1.73 m². *J Intensive Care Med.* 2022;37(6):764-768. [PubMed](#)
7. Zaki KE, Huang CW, Zhou H, et al. Comparison of safety and outcomes related to remdesivir treatment among dialysis patients hospitalized with COVID-19. *Clin Kidney J.* 2022;15(11):2056-2062. [PubMed](#)
8. Ackley TW, McManus D, Topal JE, Cicali B, Shah S. A valid warning or clinical lore: an evaluation of safety outcomes of remdesivir in patients with impaired renal function from a multicenter matched cohort. *Antimicrob Agents Chemother.* 2021; 65(2):20. [PubMed](#)

Guidelines and Recommendations

9. National Institutes of Health. Remdesivir. 2022 Aug 8; <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/>. Accessed 2022 Nov 22.
See Recommendations, page 175; Considerations in Patients With Renal Insufficiency, page 176.

Appendix 1: References of Potential Interest

Non-Randomized Studies

Population Age Not Specified

Al Bishawi A, Abdel Hadi H, Elmekaty E, et al. Remdesivir for COVID-19 pneumonia in patients with severe chronic kidney disease: a case series and review of the literature. *Clin Case Rep.* 2022;10(2):e05467. [PubMed](#)

Butt B, Hussain T, Jarrar M, et al. Efficacy and safety of remdesivir in COVID-19 positive dialysis patients. *Antibiotics (Basel).* 2022;11(2):25. [PubMed](#)

Aiswarya D, Arumugam V, Dineshkumar T, et al. Use of remdesivir in patients with COVID-19 on hemodialysis: a study of safety and tolerance. *Kidney Int Rep.* 2021;6(3):586-593. [PubMed](#)

Preprints

Brown PA, McGuinty M, Argyropoulos C, et al. Early experience with modified dose nirmatrelvir/ritonavir in dialysis patients with coronavirus disease-2019 [non peer-reviewed preprint]. *medRxiv.* 2022: doi: <https://doi.org/10.1101/2022.05.18.22275234>. <https://www.medrxiv.org/content/10.1101/2022.05.18.22275234v1> Accessed Nov 22.

Selvaraj V, Baig M, Dapaah-Afryie K, Finn A, Jindal A, Bayliss G. Outcomes of COVID-19 among patients with end stage renal disease on remdesivir. [non peer-reviewed preprint]. *medRxiv;* 2021: doi: [10.1101/2021.02.10.21251527](https://doi.org/10.1101/2021.02.10.21251527). <https://www.medrxiv.org/content/10.1101/2021.02.10.21251527v1>. Accessed 2022 Nov 22.

Alternative Population – Kidney Transplant Patients

Cacho J, Burgos E, Molina M, et al. Remdesivir in kidney transplant patients with SARS-CoV-2 pneumonia. *Nefrologia (Engl Ed).* 2022;42(3):311-317. [PubMed](#)

Gouthami B, Naik ND, Bennikal M, et al. COVID-19 in kidney transplant recipients; an Indian experience. *J Nephropathol.* 2022;11(2):e17232. <https://nephropathol.com/Article/jnp-17232>. Accessed 2022 Nov 22.

Latief M, Abbas F, Iqbal M, Hassan Z, Naresh Goud L, Shafi O. Remdesivir in renal transplant patients with coronavirus disease 2019: an observational study. *Ind J Transplant.* 2022;16(2):216-219.

Buxeda A, Arias-Cabrales C, Perez-Saez MJ, et al. Use and safety of remdesivir in kidney transplant recipients with COVID-19. *Kidney Int Rep.* 2021;6(9):2305-2315. [PubMed](#)

Meshram HS, Kute VB, Patel H, et al. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: a retrospective cohort from a developing nation. *Transpl Infect Dis.* 2021;23(4):e13629. [PubMed](#)

Tatapudi RR, Kopparti VR, Poosapati A, Metta S, Gongada AR, Vedula B. SARS-CoV-2 infection in kidney transplant recipients: a single-centre study of 20 cases from India. *Int J Nephrol.* 2021;2021:2243095. [PubMed](#)

Case Series

Ito J, Kimura M, Taya T, et al. Remdesivir administration for Japanese COVID-19 patients undergoing maintenance hemodialysis: a retrospective observation with six case reports. *Ren Replace Ther.* 2022;8(1):14. [PubMed](#)

Alternative Comparator – People Without Renal Impairment

Sunny S, Samaroo-Campbell J, Abdallah M, Luka A, Quale J. Is remdesivir safe in patients with renal impairment? Experience at a large tertiary urban medical center. *Infection.* 2022;26:26. [PubMed](#)

Pettit NN, Pisano J, Nguyen CT, et al. Remdesivir use in the setting of severe renal impairment: a theoretical concern or real risk? *Clin Infect Dis.* 2021;73(11):e3990-e3995. [PubMed](#)

Mixed Population – Patients With and Without Baseline Renal Impairment

Shakir A, Bhasin N, Swami R, et al. Renal and hepatic outcomes after remdesivir therapy in Coronavirus disease-2019-positive patients with renal dysfunction at baseline or after starting therapy. *Saudi J Kidney Dis Transpl.* 2021;32(4):1034-1042. [PubMed](#)

Guidelines and Recommendations

Unclear Methodology

BC COVID Therapeutics Committee. Clinical practice guide for the use of therapeutics in mild-moderate COVID-19. Vancouver (BC): BC Centre for Disease Control; 2022 Oct 12: http://www.bccdc.ca/Health-Professionals-Site/Documents/COVID-treatment/ClinicalPracticeGuide_Therapeutics_MildModerateCOVID.pdf. Accessed 2022 Nov 22.

See Contraindications, Nirmatrelvir/ritonavir, Remdesivir, page 11 and Dosing, Remdesivir, page 14.

Hamilton Family Medicine. Antiviral / Paxlovid access [clinical care pathway]. 2022; <https://hfam.ca/clinical-pathways-and-evidence/covid/hamilton-monoclonal-antibody-pilot/>. Accessed 2022 Nov 22.

See Writing a Prescription for Paxlovid.

Komorowski AS, Tseng A, Vandersluis S, et al. Evidence-based recommendations on the use of nirmatrelvir/ritonavir (Paxlovid) for adults in Ontario. *Science Briefs of the Ontario COVID-19 Science Advisory Table.* 2022;3(57). <https://covid19-sciencetable.ca/wp-content/uploads/2022/02/Evidence-Based-Recommendations-on-the-Use>

[-of-Nirmatrelvir-Ritonavir-Paxlovid-for-Adults-in-Ontario_published_20220223.pdf](#). Accessed 2022 Nov 22.
See Patients with Renal Impairment, page 18.

Ontario Health; Ontario Renal Network. COVID-19 supplemental clinical guidance #4: nirmatrelvir/ritonavir (Paxlovid) use in patients with advanced chronic kidney disease and patients on dialysis with COVID19. Toronto (ON): Ontario Health; 2022 Apr 13: <https://www.ontariohealth.ca/sites/ontariohealth/files/2022-04/PaxlovidClinicalGuide.pdf>. Accessed 2022 Nov 22.
See Table 2: Proposed dosing guidance for Nirmatrelvir/Ritonavir in Chronic Kidney Disease, page 10.

Marra F, Smolders EJ, El-Sherif O, et al. Recommendations for dosing of repurposed COVID-19 medications in patients with renal and hepatic impairment. *Drugs R D*. 2021;21(1):9-27. [PubMed](#)
See section 3.4.1, page 13.

Review Articles

Wilt TJ, Kaka AS, MacDonald R, et al. COVID-19: remdesivir for hospitalized adults: a living rapid review. Washington (DC): Evidence Synthesis Program, Health Services Research and Development Service, Office of Research and Development, Department of Veteran Affairs: 2022 Feb; <https://www.hsrd.research.va.gov/publications/esp/covid-19-remdesivir.pdf>. Accessed 2022 Nov 22.
See page 38; ongoing studies or studies completed after our search date.

Kusztal M, Myslak M. Therapeutic dilemmas in dialysis patients hospitalized for COVID-19: balancing between nihilism, off-label treatment and side effects. *Clin Kidney J*. 2021;14(4):1039-1041. [PubMed](#)

Roberto P, Francesco L, Emanuela C, Giorgia G, Pasquale N, Sara D. Current treatment of COVID-19 in renal patients: hope or hype? *Intern Emerg Med*. 2020;15(8):1389-1398. [PubMed](#)

Additional References

Research Letters

Cuadrado-Payan E, Rodriguez-Espinosa D, Broseta JJ, Guillen-Olmos E, Maduell F. Safety profile and clinical results of remdesivir in hemodialysis patients infected with SARS-CoV-2. A single-center Spanish cohort study. *J Nephrol*. 2022;1-2. [PubMed](#)

Lim JH, Park SD, Jeon Y, et al. Clinical effectiveness and safety of remdesivir in hemodialysis patients with COVID-19. *Kidney Int Rep*. 2022;7(11):2522-2525. [PubMed](#)

Estiverne C, Strohbehn IA, Mithani Z, et al. Remdesivir in patients with estimated GFR <30 ml/min per 1.73 m² or on renal replacement therapy. *Kidney Int Rep*. 2021;6(3):835-838. [PubMed](#)

Thakare S, Gandhi C, Modi T, et al. Safety of remdesivir in patients with acute kidney injury or CKD. *Kidney Int Rep*. 2021;6(1):206-210. [PubMed](#)

Letter to the Editor

Haddad I, Agarwal P, Hassanein M. Remdesivir use in COVID-19 patients with end-stage kidney disease on intermittent hemodialysis: an absolute contraindication? *Therap Apher Dial*. 2022;26(4):850-851. [PubMed](#)

Case Report

Patel RH, Pella PM, Haider N, Blanco R. Case report: severe SARS-CoV-2 infection treated with remdesivir in a patient with ESRD. *Infect Disord Drug Targets*. 2022;22(3):e011221198456. [PubMed](#)

Case Report – Kidney Transplant Patients

Fahim P, Nicolaysen A, Yabu JM, Zuckerman JE. Osmotic tubulopathy and acute thrombotic microangiopathy in a kidney transplant recipient with a breakthrough SARS-CoV-2 infection. *Kidney Med*. 2022;4(7):100492. [PubMed](#)